Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Biology and Medicine is Scopus-indexed (Q1, CiteScore 11.5), WoS SCIE, DOAJ. Published by Cancer Biology and Medicine.
Checked against the index lists dated .
ISSN 2095-3941Verify ISSN ↗
Publisher: Cancer Biology and Medicine
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 46 / 428 | 89th | Q1 |
| Cancer Research | 38 / 233 | 83rd | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2012–present, best quartile Q1, CiteScore 11.5.
Cancer Biology and Medicine is Q1 in Oncology (rank 46 of 428) and Q1 in Cancer Research (rank 38 of 233), by CiteScore 2025.
Cancer Biology and Medicine is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 11.5, which places it in quartile Q1 at the 89th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.888, quartile Q1, with an H-index of 78.
The publisher lists an article processing charge of about US$1,500 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Biology and Medicine is published by Cancer Biology and Medicine. Its ISSN is 2095-3941.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Cancer Biology and Medicine has an h-index of 71 and a 2-year mean of 5.21 citations per paper (OpenAlex). Its Scopus CiteScore is 11.5, quartile Q1. On 2-year citations it ranks #53 of 424 Scopus journals in Oncology.
Cancer Biology and Medicine published 120 papers in 2025; its busiest recent year was 2021 with 154. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from China (83.8%), Hong Kong SAR China (6%) and United States (4.8%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.